Search
Annovis Bio Inc
ANVSAdd to Watchlist
2.060USD
-0.060-2.82%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
71.37MMarket Cap
LossP/E TTM
More Details of Annovis Bio Inc Company
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Annovis Bio Inc Info
Ticker SymbolANVS
Company nameAnnovis Bio Inc
IPO dateJan 29, 2020
CEOMaccecchini (Maria L)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJan 29
Address101 Lindenwood Drive, Suite 225
CityMALVERN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code19355
Phone14848753192
Websitehttps://www.annovisbio.com/
Ticker SymbolANVS
IPO dateJan 29, 2020
CEOMaccecchini (Maria L)
Company Executives of Annovis Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
3.51M
+20.33%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Ms. Eve Damiano
Ms. Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
Ms. Melissa Gaines
Ms. Melissa Gaines
Senior Vice President - Clinical Operations
Senior Vice President - Clinical Operations
--
--
Dr. Mike Christie, Ph.D.
Dr. Mike Christie, Ph.D.
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Mr. Mark P. Guerin, CPA
Mr. Mark P. Guerin, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
3.51M
+20.33%
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Dr. Cheng Fang, Ph.D.
Dr. Cheng Fang, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hoffman (Michael B)
10.14%
Maccecchini (Maria-Luisa)
3.50%
Heights Capital Management, Inc.
2.89%
Vanguard Capital Management, LLC
2.52%
Marshall Wace LLP
2.10%
Other
78.87%
Shareholders
Shareholders
Proportion
Hoffman (Michael B)
10.14%
Maccecchini (Maria-Luisa)
3.50%
Heights Capital Management, Inc.
2.89%
Vanguard Capital Management, LLC
2.52%
Marshall Wace LLP
2.10%
Other
78.87%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.88%
Investment Advisor
8.44%
Investment Advisor/Hedge Fund
3.53%
Hedge Fund
1.89%
Research Firm
1.12%
Pension Fund
0.18%
Family Office
0.05%
Bank and Trust
0.03%
Other
70.88%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
109
5.17M
14.92%
+1.14M
2025Q4
95
3.04M
12.65%
--
2025Q3
100
3.04M
19.77%
+213.09K
2025Q2
100
2.82M
20.67%
-295.79K
2025Q1
97
3.12M
17.76%
-341.88K
2024Q4
86
1.59M
13.97%
+377.86K
2024Q3
78
1.21M
12.84%
+189.05K
2024Q2
74
1.03M
17.16%
-257.35K
2024Q1
70
1.29M
17.10%
-594.16K
2023Q4
71
1.27M
17.43%
-328.68K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hoffman (Michael B)
2.80M
9.87%
+45.00K
+1.63%
Dec 08, 2025
Maccecchini (Maria-Luisa)
1.21M
4.27%
+97.56K
+8.75%
Oct 28, 2025
Heights Capital Management, Inc.
1.00M
3.53%
--
--
Mar 31, 2025
Marshall Wace LLP
725.86K
2.56%
+725.86K
--
Dec 31, 2025
Two Sigma Investments, LP
597.06K
2.11%
+586.55K
+5580.32%
Dec 31, 2025
Susquehanna International Group, LLP
303.29K
1.07%
+84.87K
+38.85%
Dec 31, 2025
Geode Capital Management, L.L.C.
222.13K
0.78%
+37.98K
+20.62%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
139.53K
0.49%
+58.86K
+72.96%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
